News & Events
News & Events
Institut Pasteur Korea Partners with Sookmyung Women’s University Research Institute of Pharmaceutical Sciences to Advance Anti-Aging Therapeutics
2025-07-24
Institut Pasteur Korea Partners with Sookmyung Women’s University Research Institute of Pharmaceutical Sciences to Advance Anti-Aging Therapeutics
- Collaboration established to jointly develop innovative therapeutics
for age-related diseases in preparation for a super-aged society -
- Institut Pasteur Korea to provide advanced drug discovery infrastructure and screening platform -
for age-related diseases in preparation for a super-aged society -
- Institut Pasteur Korea to provide advanced drug discovery infrastructure and screening platform -
(July, 24, 2025, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) announced on August 24 that it signed a research collaboration agreement with the Sookmyung Women’s University Research Institute of Pharmaceutical Sciences (SMWU RIPS) on August 17 to promote joint R&D of novel therapeutics for aging-related and infectious diseases.
This agreement was established to address the demand for therapeutics targeting age-related diseases amid the transition into a super-aged society. The two institutions plan to conduct joint research by combining IPK’s research capabilities and infrastructure with SMWU RIPS’s scientific expertise.
Founded in 2004 through Korea-France scientific exchange, IPK is a research institute specializing in infectious disease R&D. With Biosafety Level 3 (BSL-3) laboratories and automated high-throughput screening platforms, IPK conducts research for the development of therapeutics and vaccines targeting infectious diseases.
Notably, IPK operates a robust cell- and image-based high-throughput/high-content screening (HTS/HCS) platform, a compound library of over 500,000 chemical entities, and an RNAi collection—resources that enable the institute to identify drug candidates across a wide spectrum of therapeutic areas, including not only infectious diseases but also age-related conditions.
SMWU RIPS has recently established the Muscle Physiome Research Center and the Gene Therapy Research Center to focus on the development of therapies for age-related diseases such as sarcopenia, stroke, osteoporosis, and elderly-onset cancers. The institute has also signed research agreements with various biotech companies, including CGBIO (regenerative medicine), Symyoo (clinical trials), and Basgenbio (big data analysis). With the newly signed agreement with IPK, the pace and efficiency of new drug discovery efforts are expected to accelerate significantly.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “We expect that our advanced infrastructure and proven drug discovery expertise, which have been cultivated through years of infectious disease research, will also generate meaningful outcomes in the field of aging-related therapeutics.”
Chang-Young Jang, Director of SMWU RIPS, added, “This collaboration brings together our research strengths in drug mechanism and disease pathology with IPK’s cutting-edge screening and discovery capabilities. We anticipate that this joint effort will deliver foundational research results that ultimately contribute to global health.”
This agreement was established to address the demand for therapeutics targeting age-related diseases amid the transition into a super-aged society. The two institutions plan to conduct joint research by combining IPK’s research capabilities and infrastructure with SMWU RIPS’s scientific expertise.
Founded in 2004 through Korea-France scientific exchange, IPK is a research institute specializing in infectious disease R&D. With Biosafety Level 3 (BSL-3) laboratories and automated high-throughput screening platforms, IPK conducts research for the development of therapeutics and vaccines targeting infectious diseases.
Notably, IPK operates a robust cell- and image-based high-throughput/high-content screening (HTS/HCS) platform, a compound library of over 500,000 chemical entities, and an RNAi collection—resources that enable the institute to identify drug candidates across a wide spectrum of therapeutic areas, including not only infectious diseases but also age-related conditions.
SMWU RIPS has recently established the Muscle Physiome Research Center and the Gene Therapy Research Center to focus on the development of therapies for age-related diseases such as sarcopenia, stroke, osteoporosis, and elderly-onset cancers. The institute has also signed research agreements with various biotech companies, including CGBIO (regenerative medicine), Symyoo (clinical trials), and Basgenbio (big data analysis). With the newly signed agreement with IPK, the pace and efficiency of new drug discovery efforts are expected to accelerate significantly.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “We expect that our advanced infrastructure and proven drug discovery expertise, which have been cultivated through years of infectious disease research, will also generate meaningful outcomes in the field of aging-related therapeutics.”
Chang-Young Jang, Director of SMWU RIPS, added, “This collaboration brings together our research strengths in drug mechanism and disease pathology with IPK’s cutting-edge screening and discovery capabilities. We anticipate that this joint effort will deliver foundational research results that ultimately contribute to global health.”